TargetKappa-type opioid receptor(Cavia porcellus (domestic guinea pig))
University Of Minnesota
Curated by ChEMBL
University Of Minnesota
Curated by ChEMBL
Affinity DataKi: 0.310nMAssay Description:Binding affinity towards Opioid receptor kappa 1 in guinea pig brainMore data for this Ligand-Target Pair
TargetKappa-type opioid receptor(Cavia porcellus (domestic guinea pig))
University Of Minnesota
Curated by ChEMBL
University Of Minnesota
Curated by ChEMBL
Affinity DataKi: 0.910nMAssay Description:Binding affinity towards Opioid receptor kappa 1 in guinea pig brainMore data for this Ligand-Target Pair
Affinity DataKi: 18nMAssay Description:Binding affinity towards delta-1 opioid receptor in guinea pig brainMore data for this Ligand-Target Pair
Affinity DataKi: 44nMAssay Description:Binding affinity towards delta-2 opioid receptor in guinea pig brainMore data for this Ligand-Target Pair
Affinity DataKi: 90nMAssay Description:Inhibitory activity against L-arginine binding to Inducible nitric oxide synthaseMore data for this Ligand-Target Pair
Affinity DataKi: 96nMAssay Description:Binding affinity towards delta-1 opioid receptor in guinea pig brainMore data for this Ligand-Target Pair
Affinity DataKi: 264nMAssay Description:Binding affinity towards delta-2 opioid receptor in guinea pig brainMore data for this Ligand-Target Pair
Affinity DataKi: 286nMAssay Description:Binding affinity towards Opioid receptor mu 1 in guinea pig brainMore data for this Ligand-Target Pair
Affinity DataKi: 631nMAssay Description:Binding affinity towards Opioid receptor mu 1 in guinea pig brainMore data for this Ligand-Target Pair
Affinity DataKi: 5.49E+3nMAssay Description:Inhibition of human recombinant LSD1 assessed as inhibition constant by HRP-coupled assayMore data for this Ligand-Target Pair
Ligand Info
TargetTyrosine-protein phosphatase non-receptor type 1 [1-298](Homo sapiens (Human))
Procter & Gamble Pharmaceuticals
Procter & Gamble Pharmaceuticals
Affinity DataKi: 2.40E+4nM ΔG°: -26.1kJ/molepH: 7.0 T: 2°CAssay Description:The activity of PTP1B enzyme was assayed with DiFMUP as substrate. Hydrolysis of substrate was monitored on a Victor V plate reader (Wallac). Kinetic...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 1 [1-298](Homo sapiens (Human))
Procter & Gamble Pharmaceuticals
Procter & Gamble Pharmaceuticals
Affinity DataKi: >5.00E+5nMAssay Description:The activity of PTP1B enzyme was assayed with DiFMUP as substrate. Hydrolysis of substrate was monitored on a Victor V plate reader (Wallac). Kinetic...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.0100nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.0100nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.0100nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.0100nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: <0.0720nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: <0.0720nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: <0.0720nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: <0.0720nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.0800nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.0800nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.0800nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.0800nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.0800nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.0800nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.0800nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.0800nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.0860nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.0900nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.0900nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.0900nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.0900nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.0970nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.0990nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.100nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.100nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.100nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.100nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.100nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.100nMAssay Description:Non-limiting examples of the HPTPβ IC50 (μM) activity.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.100nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.100nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.100nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.100nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.100nMAssay Description:Non-limiting examples of the HPTP-β IC50(μM) activity for illustrative compounds are listed in TABLE 2.More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Eyepoint Pharmaceuticals
US Patent
Eyepoint Pharmaceuticals
US Patent
Affinity DataIC50: 0.100nMAssay Description:Non-limiting examples of the HPTP-β IC50 (μM) activity.More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.113nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.120nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
Affinity DataIC50: 0.120nMAssay Description:Inhibitory activity against Opioid receptor kappa 1 in electrically stimulated mouse vas deferens (MVD) preparation.More data for this Ligand-Target Pair